Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:CMND NASDAQ:KTTA NASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.99+0.6%$0.98$0.55▼$1.19$12.56M0.83169,155 shs227,087 shsCMNDClearmind Medicine$3.07-2.2%$5.56$2.10▼$524.00$3.20M0.644.64 million shs1.28 million shsKTTAPasithea Therapeutics$0.50+0.1%$0.70$0.28▼$2.06$12.53M0.25468,574 shs196,337 shsPHIOPhio Pharmaceuticals$1.03-4.6%$1.15$0.81▼$4.19$12.55M0.82138,702 shs254,275 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+1.98%+13.67%+23.47%+14.66%+55.22%CMNDClearmind Medicine0.00%-1.88%-17.39%-52.08%-99.07%KTTAPasithea Therapeutics-1.51%-13.43%-34.77%-35.78%-37.13%PHIOPhio Pharmaceuticals+1.89%+1.89%0.00%-8.47%-55.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.99+0.6%$0.98$0.55▼$1.19$12.56M0.83169,155 shs227,087 shsCMNDClearmind Medicine$3.07-2.2%$5.56$2.10▼$524.00$3.20M0.644.64 million shs1.28 million shsKTTAPasithea Therapeutics$0.50+0.1%$0.70$0.28▼$2.06$12.53M0.25468,574 shs196,337 shsPHIOPhio Pharmaceuticals$1.03-4.6%$1.15$0.81▼$4.19$12.55M0.82138,702 shs254,275 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+1.98%+13.67%+23.47%+14.66%+55.22%CMNDClearmind Medicine0.00%-1.88%-17.39%-52.08%-99.07%KTTAPasithea Therapeutics-1.51%-13.43%-34.77%-35.78%-37.13%PHIOPhio Pharmaceuticals+1.89%+1.89%0.00%-8.47%-55.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 2.00HoldN/AN/ACMNDClearmind Medicine 0.00N/AN/AN/AKTTAPasithea Therapeutics 2.00Hold$3.00496.42% UpsidePHIOPhio Pharmaceuticals 2.00Hold$14.001,259.22% UpsideCurrent Analyst Ratings BreakdownLatest CMND, KTTA, BFRI, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.006/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$41.71M0.30N/AN/A$0.90 per share1.10CMNDClearmind MedicineN/AN/AN/AN/A$11.28 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$10.54M-$0.97N/A16.45N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)CMNDClearmind Medicine-$3.86M-$197.20N/AN/AN/AN/A-143.79%-88.51%N/AKTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)PHIOPhio Pharmaceuticals-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)Latest CMND, KTTA, BFRI, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q2 2026CMNDClearmind MedicineN/A-$6.78N/A-$6.78N/AN/A5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/7/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24-$0.34-$0.10-$0.34N/AN/A3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/A3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera0.781.201.09CMNDClearmind MedicineN/A4.793.79KTTAPasithea TherapeuticsN/A35.4135.41PHIOPhio PharmaceuticalsN/A18.3218.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%CMNDClearmind Medicine96.05%KTTAPasithea Therapeutics23.92%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera8.10%CMNDClearmind MedicineN/AKTTAPasithea Therapeutics2.00%PHIOPhio Pharmaceuticals0.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7012.80 million11.77 millionNo DataCMNDClearmind MedicineN/A1.02 millionN/ANot OptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionablePHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionableCMND, KTTA, BFRI, and PHIO HeadlinesRecent News About These CompaniesPhio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026June 18 at 5:53 PM | finance.yahoo.comPhio Pharmaceuticals to Participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesMay 27, 2026 | tennessean.comTPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 8, 2026 | finanznachrichten.dePhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 7, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...April 14, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026April 13, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026April 9, 2026 | finance.yahoo.comPyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology CandidateApril 8, 2026 | jsonline.comJPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 31, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 30, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...March 23, 2026 | finance.yahoo.comPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline AdvancementMarch 23, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | newsfilecorp.comNB2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured ConferenceMarch 11, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | finanznachrichten.dePhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMND, KTTA, BFRI, and PHIO Company DescriptionsBiofrontera NASDAQ:BFRI$0.99 +0.01 (+0.61%) Closing price 04:00 PM EasternExtended Trading$0.98 -0.01 (-1.11%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Clearmind Medicine NASDAQ:CMND$3.07 -0.07 (-2.23%) Closing price 04:00 PM EasternExtended Trading$3.06 -0.01 (-0.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Pasithea Therapeutics NASDAQ:KTTA$0.50 +0.00 (+0.14%) Closing price 03:59 PM EasternExtended Trading$0.52 +0.01 (+2.39%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Phio Pharmaceuticals NASDAQ:PHIO$1.03 -0.05 (-4.63%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.02 (+2.43%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
